Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for November 13, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026 HILLSIDE, NEW JERSEY (November 13, 2026) - Integrated BioPharma,
How this was made
The 30-second read
Why it matters
The earnings shortfall signals short‑term weakness, but forward‑looking statements hint at possible upside if new products launch successfully.
Market read
Micro‑cap earnings miss with a 22% revenue decline; likely to trigger a modest sell‑off in the OTC market.
What to watch
The filing notes forward‑looking statements about new product introductions and potential regulatory approvals that could improve future outlook.
Background
Integrated BioPharma is an OTCQX listed contract manufacturer of vitamins and supplements. The 8‑K filing provides its first public quarterly results for Q3 2026.
Ticker impact
Integrated BioPharma disclosed its Q3 2026 earnings, reporting a 22% revenue decline and a net loss of $0.7M.
likely pressure as the market prices in the revenue decline and loss
Micro‑cap earnings miss with no offsetting guidance typically triggers a sell‑off.
Market effects
May weigh on other nutraceutical contract manufacturers as a peer shows revenue contraction.
Limited to OTCQX market; no broader regional effect.
Minimal global impact due to small size and niche focus.
Counterpoint
If the company can retain its two largest customers, the revenue base may stabilize, offering a buying opportunity at depressed prices.
Key entities
- companyIntegrated BioPharma Inc.
OTCQX listed contract manufacturer of nutraceuticals.
